Sign In
Buy BNTX
$91.35
-0.90 (-0.98%)
At Close: Aug 04, 2026
Does This Vaccine-Maker's Upcoming Share Repurchase Make It a Buy?
10:07am, Friday, 22'nd Apr 2022
It could be an important sign of a transitional period to come.
Novavax (NVAX) Posts Upbeat Data on COVID/Flu Combo Jab Study
03:58pm, Thursday, 21'st Apr 2022 Zacks Investment Research
Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.
2 Monster Stocks to Buy Without Any Hesitation
03:37pm, Thursday, 21'st Apr 2022 The Motley Fool
These healthcare giants know something about beating the market.
Moderna (MRNA) Posts Upbeat Data on Bivalent COVID Booster Jab
02:02pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.
Moderna is developing a COVID-19 booster that protects against omicron and the original virus
12:05pm, Wednesday, 20'th Apr 2022 MarketWatch
The company said it expects to have clinical data for this shot by the end of June.
3 Top Biotech Stocks Ready for a Bull Run
11:40am, Wednesday, 20'th Apr 2022 The Motley Fool
The hype has died down. Now it's time for science to take over.
3 Top Biotech Stocks Ready for a Bull Run
07:40am, Wednesday, 20'th Apr 2022
The hype has died down. Now it's time for science to take over.
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
10:00pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $159.74, moving +0.11% from the previous trading session.
Why Ocugen Stock Tumbled by Nearly 6% Today
11:25pm, Monday, 18'th Apr 2022 The Motley Fool
Investors were probably concerned the expansion of a licensing deal was pricey.
Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids
06:27pm, Monday, 18'th Apr 2022 Zacks Investment Research
A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.
Why BioNTech, Moderna, and Novavax Stocks Are Sinking Today
05:39pm, Monday, 18'th Apr 2022 The Motley Fool
Each vaccine stock is moving lower for a different reason.
Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids
03:48pm, Monday, 18'th Apr 2022
A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.
Why BioNTech, Moderna, and Novavax Stocks Are Sinking Today
01:39pm, Monday, 18'th Apr 2022
Each vaccine stock is moving lower for a different reason.
Pfizer/BioNTech Fourth COVID-19 Vaccine Dose Protects Against Omicron For At Least One Month
12:27pm, Monday, 18'th Apr 2022
A fourth dose of the COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) provided significant protection against severe disease, hospitalization, and death for at least a m
Novavax (NVAX) COVID Jab Gets Nod for Use in Switzerland
07:27pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Novavax's (NVAX) Nuvaxovid is the first protein COVID-19 vaccine authorized for use in Switzerland. The stock price rises following the announcement.
